Shukra Pharmaceuticals Limited (SHUKRAPHAR) fundamentals
Shukra Pharmaceuticals Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SHUKRAPHAR (ISIN INE551C01044). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Shukra Pharmaceuticals Limited does
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.
Valuation and market data
| Last close | ₹54.00 |
|---|---|
| Market capitalisation | ₹2,351 crore |
| Enterprise value | ₹2,346 crore |
| P/E (TTM) | 0.00 |
| Price to book | 37.42 |
| Price to sales (TTM) | 29.81 |
| Book value per share | ₹1.44 |
| Dividend yield | 1.85% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Fri Aug 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹61 crore | ₹29 crore | ₹22 crore | 0.00 |
| Mar 2025 | ₹37 crore | ₹13 crore | ₹10 crore | 0.22 |
| Mar 2024 | ₹77 crore | ₹20 crore | ₹19 crore | 16.93 |
| Mar 2023 | ₹60 crore | ₹4 crore | ₹4 crore | 26.21 |
| Mar 2022 | ₹21 crore | ₹1 crore | ₹1 crore | 4.79 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Aug 2026:
| Promoters | 51.1% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 48.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.